LIST OF EORTC ACCEPTED ABSTRACTS
At the American Society of Clinical Oncology (ASCO)
New Orleans, Louisiana, 5 - 8June 2004

Link to Abstracts texts

  1. Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): An EORTC Phase II Trial (08984). (Poster presentation)

    Manegold: Saturday June 5, General Poster Session, 8.00-12.00, Hall A (right half), abs 7166, poster #Y10
  2. Predicting survival with health related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial. (Poster presentation)

    Efficace: Saturday June 5, General Poster Session, 8.00-12.00, Hall A (right half), abs. 618, poster #D3
  3. Intraperitoneal or intraportal 5 FU combined with systemic chemotherapy for the adjuvant treatment of colorectal cancer: An EORTC (40911) and FFCD (9204) phase III study.

    Nordlinger: Saturday June 5, Poster Presentation, 1.00-5.00, Hall A (right half), abs. 3620, Poster M5.
  4. Chronomodulated (Chrono) vs constant (Cst) rate infusional 5-fluorouracil (FU) with or without cisplatin (CDDP) in patients with advanced or metastatic pancreatic cancer. A multicenter randomized trial of the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer (EORTC 05962)

    Levi: Saturday June 5, Poster Presentation, 1.00-5.00, Hall A (right half), abs. 4117, Poster W10
  5. Late non-malignant complications in aggressive non-Hodgkin’s lymphoma across four randomized EORTC-trials

    Moser: Saturday June 5, Poster Presentation, 1.00-5.00, 291 (Escalator 7), abs. 6528, Poster #11
  6. First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults

    Lindner: Saturday June 5, Poster Presentation, 1.30-5.30, 356 (escalators 3&4), abs. 9015, Poster #7
  7. Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). (Oral presentation)

    Bolla: Saturday June 5, Oral Presentation, 3.00-3.15, C2 (entrance inside the atrium restaurant), abs 4504
  8. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily Imatinib dose of 800 mg (HD) after progression on 400 mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. (Oral presentation)

    Zalcberg: Sunday June 6, Oral presentation, 7.45-8.00, 278 (escalators 5&6), abs 9004
  9. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

    Raymond: Sunday June 6, Oral Presentation, 8.00-8.15, R04 (2nd floor, escalators 1&2), abs 1501
  10. First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer : 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963).

    Giachetti: Sunday June 6, Poster Presentation, 8.00-12.00, R06, R06 (2nd floor escalators 1&2), abs 3526, Poster #17
  11. Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). (Poster presentation)

    Gorlia: Sunday June 6, Poster Presentation, 8.00-12.00, Hall A (right half), abs.9599, Poster #EE6
  12. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. (Poster presentation

    Lefèbvre: Sunday June 6, Poster Discussion, 1.00 – 5.00, R02 (2nd floor escalators 1&2), abs. 5531, Poster #23
  13. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – A randomized phase III trial of the EORTC Breast Group

    Paridaens: Sunday June 6, Oral Presentation, 1.00-1.15, Hall F, abs. 515
  14. First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival.

    Kristensen: Sunday June 6, Oral Presentation, 1.45-2.00, 355 (escalators 3&4), abs. 5003
  15. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG.

    Pfisterer: Sunday June 6, Oral Presentation, 2.30-2.45, 355 (escalators 3&4), abs. 5005
  16. Does the addition of chemotherapy (CT) to preoperative radiotherapy (RT) increase the pathological response in patients with resected rectal cancer : Report of the 22921 EORTC phase III trial. (Oral presentation)

    Bosset: Sunday June 6, Oral presentation 3.05-3.20, Hall G, abs. 3504
  17. Phase III study of Bec2/BCG vaccination as maintenance therapy in patients with limited disease small cell lung cancer, responding to chemo-radiation (EORTC 08971, the Silva study). (Late breaking abstract)

    Giaccone: Monday June 7, Oral Presentation, 8.30-8.45, Auditorium (2nd floor, escalators 6&7), abs. 7020
  18. A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC.(Late breaking abstract)

    Van Meerbeek: Monday June 7, Oral Presentation, 8.45-9.00, Auditorium (2nd floor, escalators 6&7), abs. 7021
  19. Is prostate-specific antigen a surrogate for survival in advanced prostate cancer? (Poster presentation)

    Collette: Monday June 7, Poster Discussion, 8.00-12.00, 291 (Escalator 7), abs 4551, Poster #1
  20. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. (Oral presentation)

    Stupp: Monday June 7, Oral Presentation (Plenary), 2.15-2.30, Hall F, abs. 2
  21. A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982.

    Oliver: Monday June 7, Oral Presentation, 9.15-9.30, B2 (Hall B Lobby), abs 4517
  22. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer

    Vermorken: Tuesday June 8, Oral Presentation, 11.45-12.00, 355 (escalators 3&4), abs. 5508
  23. Pooled analysis (n=8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer.